regulatory status is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-06-01. Numbers and descriptions here follow the published literature rather than marketing material.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
Rosalyn Higgins, Baroness Higgins (born 2 June 1937); author of several influential works on international law, including Problems and Process: International Law and How We Use It (1994); former president of International Court of Justice (ICJ); was first female judge elected to the ICJ, and was elected to three-year term as president in 2006; became Queen's Counsel (QC) in 1986, and is bencher of the Inner Temple; served on the UN Human Rights Committee for 14 years; resigned from the Human Rights Committee when she was elected to the International Court of Justice on 12 July 1995, re-elected on 6 February 2000, and ended her second term on 6 February 2009. Her professional appointments include Specialist in International Law, Royal Institute of International Affairs, 1963–1974; Visiting Fellow, London School of Economics, 1974–1978;Professor of International Law, University of Kent at Canterbury, 1978–1981; Professor of International Law, University of London (London School of Economics), 1981–1995; Vice President, British Institute of International and Comparative Law; Member of the UN Human Rights Committee. David Hirsh (born 29 September 1967) author and scholar; professor in Sociology at Goldsmiths, University of London, and co-founder of Engage, a campaign against the academic boycott of Israel. Eric Hobsbawm Marxist historian of Viennese Jewish origin. Anthony Horowitz works include the Alex Rider series Eva Ibbotson (née Wiesner; 21 January 1925 – 20 October 2010) was an Austrian-born British novelist, known for her children's literature.
Apart from being found in high concentrations in the liver, ALT is found in the kidneys, heart, and muscles. It catalyses the transamination reaction, and only exists in a cytoplasmic form. Any kind of liver injury can cause a rise in ALT. A rise of up to 300 IU/L is not specific to the liver, but can be due to the damage of other organs such as the kidneys or muscles. When ALT rises to more than 500 IU/L, causes are usually from the liver. It can be due to hepatitis, ischemic liver injury, and toxins that causes liver damage. The ALT levels in hepatitis C rises more than in hepatitis A and B. Persistent ALT elevation more than 6 months is known as chronic hepatitis. Alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), fat accumulation in liver during childhood obesity, steatohepatitis (inflammation of fatty liver disease) are associated with a rise in ALT. Rise in ALT is also associated with reduced insulin response, reduced glucose tolerance, and increased free fatty acids and triglycerides. Bright liver syndrome (bright liver on ultrasound suggestive of fatty liver) with raised ALT is suggestive of metabolic syndrome. In pregnancy, ALT levels would rise during the second trimester. In one of the studies, measured ALT levels in pregnancy-related conditions such as hyperemesis gravidarum was 103.5 IU/L, pre-eclampsia was 115, HELLP syndrome was 149. ALT levels would reduce by greater than 50% in three days after child delivery.
"Two New Cyathane Diterpenoids from Mycelial Cultures of the Medicinal Mushroom Hericium erinaceus and the Rare Species, Hericium flagellum". International Journal of Molecular Sciences. 19 (3): 740. Bibcode:2018IJMSc..19..740R. doi:10.3390/ijms19030740. ISSN 1422-0067. PMC 5877601. PMID 29509661. A-C, Za, Zb, Zc, T, P, Q, X, W, Y Ma, Ke; Zhang, Yuting; Guo, Cui; Yang, Yanlong; Han, Junjie; Yu, Bo; Yin, Wenbing; Liu, Hongwei (2021-09-01). "Reconstitution of biosynthetic pathway for mushroom-derived cyathane diterpenes in yeast and generation of new "non-natural" analogues". Acta Pharmaceutica Sinica B. 11 (9): 2945–2956. doi:10.1016/j.apsb.2021.04.014. ISSN 2211-3835. PMC 8463280. PMID 34589407. S Chen, Chien-Chih; Tzeng, Tsai-Teng; Chen, Chin-Chu; Ni, Ching-Li; Lee, Li-Ya; Chen, Wan-Ping; Shiao, Young-Ji; Shen, Chien-Chang (2016-02-26). "Erinacine S, a Rare Sesterterpene from the Mycelia of Hericium erinaceus". Journal of Natural Products. 79 (2): 438–441. Bibcode:2016JNAtP..79..438C. doi:10.1021/acs.jnatprod.5b00474. ISSN 1520-6025. PMID 26807743. Retrieved 2026-01-30. A-I, P, Q, J, K, R, S, T, U, V, Z1, Z2 Qiu, Yue; Lin, Genglan; Liu, Weiming; Zhang, Fuming; Linhardt, Robert J.; Wang, Xingli; Zhang, Anqiang (July 2024). "Bioactive compounds in Hericium erinaceus and their biological properties: a review". Food Science and Human Wellness. 13 (4): 1825–1844. doi:10.26599/FSHW.2022.9250152. ISSN 2213-4530. Retrieved 2026-01-30.
Sources: en.wikipedia.org
== Efficacy == The use of lasers in treating periodontal disease has been seen by some dental professionals as controversial. The American Academy of Periodontology stated in 1999 that it was "not aware of any randomized blinded controlled longitudinal clinical trials, cohort or longitudinal studies, or case-controlled studies indicating that 'laser excisional new attachment procedure (or Laser ENAP)' or 'laser curettage' offers any advantageous clinical result not achieved by traditional periodontal therapy. Moreover, published studies suggest that use of lasers for ENAP procedures and/or gingival curettage could render root surfaces and adjacent alveolar bone incompatible with normal cell attachment and healing." A 2015 systematic review from the AAP regeneration workshop acknowledged peer-reviewed studies reporting periodontal regeneration, and further suggested that the LANAP protocol's minimally invasive nature may offer advantages in the regeneration of defects where minimal soft tissue change is required. The AAP consumer information page on laser therapy for gum disease notes that lasers can be used to treat periodontal disease and that controlled studies have reported similar results to some other treatment options (including scaling and root planing alone), and also states that different laser wavelengths have different applications in periodontal treatment.
==== Design principles ==== Practical applications of MOFs for hydrogen storage are met with several challenges. For hydrogen adsorption near room temperature, the hydrogen binding energy would need to be increased considerably. Several classes of MOFs have been explored, including carboxylate-based MOFs, heterocyclic azolate-based MOFs, metal-cyanide MOFs, and covalent organic frameworks. Carboxylate-based MOFs have by far received the most attention because
may our temples be true harmonious ensembles of moral peace, civic education, and constant example for the work of good, which are so necessary in the current times that our Republic is going through... Not only the fulfillment of our Masonic duties, but the satisfaction as citizens of a Free homeland, to which we lend our selfless support, for the strengthening of republican institutions." On September 27, 1921, the Upper House of the Grand Lodge integrated the Association of Veteran Masons into its structure, where it had been an independent constituent of Cuban Freemasonry since 1893. In 1947, the Grand Lodge and the Supreme Council ratified the Treaty of Friendship and Mutual Recognition. On September 15, 1949, Grand Master Carlos M. Piñeiro y del Cueto issued Decree No. 284, creating the Cuban Academy of High Masonic Studies. In 1936, there were 195 Lodges in Cuba. From 1945 to 1959, the membership of Freemasonry in Cuba had doubled. By 1959, there were over 34,000 Freemasons in Cuba. By the time of the collapse of the Republic of Cuba, the Grand Lodge of Cuba maintained 400 regular Lodges.
The National Postgraduate Medical College of Nigeria (NPMCN): Established in 1979, NPMCN is responsible for the training and certification of medical and dental specialists within Nigeria. The West African Postgraduate Medical Colleges: These are the West African College of Physicians (WACP) and the West African College of Surgeons (WACS), which coordinate regional training and certification across West Africa.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.